Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Net Receivables

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Net Receivables

NTHI · NASDAQ
CompanyNet Receivables
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
472.00K
-48.0%-30.9%34.2%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
13.92M
146.2%127.4%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
7.39M
24.3%-19.0%N/A
0.00
N/AN/AN/A
974.00K
182.9%23.7%N/A
1.50M
N/AN/A1.2%
0.00
N/AN/AN/A
10.51M
37.2%10.6%7.3%
1.26M
73.2%14.7%N/A
95.00K
-1.4%-4.7%N/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35